T CELL ACTIVATION AND FUNCTIONAL AVIDITY
T CELL ACTIVATION AND FUNCTIONAL AVIDITY
批准号:
8173191
负责人:
MARK K SLIFKA
金额:
$4.76万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2011-04-30
关键词:
AcuteAntigensAntiviral AgentsAvidityBiological AssayCD8B1 geneCellsComputer Retrieval of Information on Scientific Projects DatabaseDataDoseFundingGrantInstitutionKineticsLymphocytic choriomeningitis virusMeasuresMediatingMusPeptide/MHC ComplexPeptidesPhenotypeProductionPublishingResearchResearch PersonnelResourcesSourceSurfaceT cell responseT-Cell ReceptorT-LymphocyteTransgenic MiceUnited States National Institutes of HealthVacciniaVirus Diseasescytokine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
We have analyzed antigen-specific T cells directly ex vivo using peptide/MHC-tetramers and functional assays that
measure cytolytic activity and cytokine production. Following acute viral infection, we have found that T cell responsiveness (termed
functional avidity) to peptide antigen increased significantly in both normal and T cell receptor (TcR) transgenic mice, even though TcR
avidity remained virtually unaltered.
Little is known about the factors involved with determining the kinetics or degree of functional avidity maturation. In our recent studies, we have published a review describing T cell attributes and how they can be modified by adaptive (i.e., peptide stimulation) vs. innate (i.e., cytokine-mediated stimulation) mechanisms of activation. We have also determined the surface phenotype of T cells with high functional avidity. Prior studies had suggested that CTLA-4+ T cells had lower functional avidity than CTLA-4- T cells. Our data refutes this previous observation as we show that CD8+ T cells from LCMV-infected mice respond equally well against graded doses of specific peptide or graded doses of anti-CD3 stimulation, regardless of their expression of CTLA-4 molecules. This is significant because CTLA-4 is considered the predominant down-regulatory molecule on T cells and we show that this is not the case, at least in terms of antiviral T cell responses against either LCMV or vaccinia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8267908
-
项目类别:
-
资助金额:$132.76万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8840142
-
项目类别:
-
资助金额:$151.33万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8651871
-
项目类别:
-
资助金额:$148.82万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
Development of an H2O2-Inactivated Dengue Virus Vaccine
-
批准号:8463114
-
项目类别:
-
资助金额:$158.91万
-
财政年份:2012
-
负责人:MARK K SLIFKA
-
依托单位:
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED
-
批准号:8357801
-
项目类别:
-
资助金额:$5.82万
-
财政年份:2011
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS
-
批准号:8357802
-
项目类别:
-
资助金额:$10.91万
-
财政年份:2011
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS
-
批准号:8173258
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
YELLOW FEVER VACCINATION OF THE AGED AND IMMUNOCOMPROMISED
-
批准号:8173291
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A SAFE AND EFFECTIVE VACCINE AGAINST WEST NILE VIRUS
-
批准号:8173292
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
VACCINE-INDUCED CD8+ T CELL MEMORY
-
批准号:8173257
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
CYTOKINE-MEDIATED T CELL ACTIVATION
-
批准号:8173199
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2010
-
负责人:MARK K SLIFKA
-
依托单位:
VACCINE-INDUCED CD8+ T CELL MEMORY
-
批准号:7958529
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:7644679
-
项目类别:
-
资助金额:$79.65万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a new yellow fever vaccine for vulnerable populations
-
批准号:7676346
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
DEVELOPMENT OF A YELLOW FEVER VACCINE FOR VULNERABLE POPULATIONS
-
批准号:7958530
-
项目类别:
-
资助金额:$6.04万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:8238380
-
项目类别:
-
资助金额:$109.74万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
T CELL ACTIVATION AND FUNCTIONAL AVIDITY
-
批准号:7958426
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:8054391
-
项目类别:
-
资助金额:$303.98万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
CYTOKINE-MEDIATED T CELL ACTIVATION
-
批准号:7958438
-
项目类别:
-
资助金额:$8.03万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
Development of a Safe and Effective Vaccine Against West Nile Virus
-
批准号:7797564
-
项目类别:
-
资助金额:$212.83万
-
财政年份:2009
-
负责人:MARK K SLIFKA
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: